title: Fms-like tyrosine kinase-3 ligand alters antigen-specific responses to infections after severe burn injury.
abstract: Burn patients are susceptible to opportunistic infections partly because of decreased immune functions, especially TH1-driven antigen-specific responses, which are regulated by dendritic cells. The dendritic cell growth factor, fms-like tyrosine kinase-3 ligand (FL), has been shown to increase resistance to Pseudomonas aeruginosa, in a dendritic cell-dependent manner, in a mouse model of burn wound infection. The specific mechanisms of protection are not known. This study tested the hypothesis that FL can enhance production of P. aeruginosa-specific antibodies after burn wound infection. Mice that had been previously exposed to P. aeruginosa were infected after burn injury by wound inoculation or challenged by intraperitoneal injection of heat-killed P. aeruginosa. In response to wound infection, FL treatments enhanced bacterial clearance and induced a shift from immunoglobulin (Ig) M toward IgG and IgA. However, serum levels of neither P. aeruginosa-specific antibodies nor interferon gamma (IFN-gamma) were significantly increased by FL, possibly because of decreased systemic exposure to bacteria. After challenge with heat-killed bacteria, which ensured equal exposures, FL-treated mice produced significantly greater levels of P. aeruginosa-specific IgG2a, which correlated with an increase in serum levels of interferon gamma and enhanced opsonization capacity. IL-12, IL-10, and transforming growth factor beta were significantly increased in FL-treated mice, regardless of the type of challenge. These findings indicate that FL treatments after burn injury enhance cytokine responses to recall antigens and increase bacterial clearance. In addition, through its ability to promote TH1-associated antigen-specific responses, FL may have potential as an immunotherapy to enhance adaptive immunity after severe burn injury.
authors.affiliation: Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas 77555-0591, USA. jkbohann@utmb.edu
authors.forename: Julia
authors.initials: J
authors.lastname: Bohannon
authors.forename: Geping
authors.initials: G
authors.lastname: Fang
authors.forename: Weihua
authors.initials: W
authors.lastname: Cui
authors.forename: Edward
authors.initials: E
authors.lastname: Sherwood
authors.forename: Tracy
authors.initials: T
authors.lastname: Toliver-Kinsky
mesh_terms: D056704:Adaptive Immunity / Q000187:drug effects*; D000818:Animals; D002056:Burns / Q000188:drug therapy / Q000382:microbiology*; D003713:Dendritic Cells / Q000276:immunology; D007070:Immunoglobulin A / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology; D007371:Interferon-gamma / Q000097:blood; D016753:Interleukin-10 / Q000097:blood; D018664:Interleukin-12 / Q000097:blood; D008297:Male; D008565:Membrane Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D011552:Pseudomonas Infections / Q000276:immunology* / Q000517:prevention & control; D011550:Pseudomonas aeruginosa / Q000502:physiology
chemical_list: D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008565:Membrane Proteins; C084881:flt3 ligand protein; D016753:Interleukin-10; D018664:Interleukin-12; D007371:Interferon-gamma